# An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis

> **NCT03664960** · PHASE2 · COMPLETED · sponsor: **Allakos Inc.** · enrollment: 58 (actual)

## Conditions studied

- Eosinophilic Gastritis
- Eosinophilic Gastroenteritis
- Eosinophilic Duodenitis

## Interventions

- **DRUG:** AK002

## Key facts

- **NCT ID:** NCT03664960
- **Lead sponsor:** Allakos Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-14
- **Primary completion:** 2021-11-02
- **Final completion:** 2021-11-02
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2024-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03664960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03664960, "An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT03664960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*